Jennifer N. Durham
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jennifer N. Durham has a total of 291 co-authors. Here are the top co-authors by number of shared publications:
- Channing Judith Paller
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD
151 shared publications - Hao Wang
Sidney Kimmel Comprehensive Cancer Center 1 Baltimore, Maryland
135 shared publications - Daniel A. Laheru
Johns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland
131 shared publications - Marianna L. Zahurak
Department of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
117 shared publications - Adel Mandl
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD
116 shared publications - Aliya Lalji
Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland. 1
116 shared publications
Latest Publications
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from A Randomized Phase II Study: CRS207/GVAX plus Anti–PD‐1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells into PDAC
Expression profiles of immune cell clusters using a myeloid-focused panel of antibodies
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from A Randomized Phase II Study: CRS207/GVAX plus Anti–PD‐1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells into PDAC
Expression profiles of immune cell clusters using a myeloid-focused panel of antibodies
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from A Randomized Phase II Study: CRS207/GVAX plus Anti–PD‐1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells into PDAC
Representativeness of Study Participants
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from A Randomized Phase II Study: CRS207/GVAX plus Anti–PD‐1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells into PDAC
Representativeness of Study Participants
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from A Randomized Phase II Study: CRS207/GVAX plus Anti–PD‐1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells into PDAC
Suspension Mass Cytometry Antibodies
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from A Randomized Phase II Study: CRS207/GVAX plus Anti–PD‐1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells into PDAC
Suspension Mass Cytometry Antibodies
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Data from A Randomized Phase II Study: CRS207/GVAX plus Anti–PD‐1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells into PDAC
Pancreatic ductal adenocarcinoma (PDAC) remains highly lethal and has poor immunogenicity, warranting the use of vaccines to guide and recruit the immune response. Building on prior efforts to achieve clinical immunotherapeutic responses against PDAC, we conducted a phase II study (NCT03190265) that combined attenuated mesothelin (MSLN)-secreting listeria vaccine (CRS-207) and GM-CSF–secreting allogeneic whole-cell vaccine (GVAX) along with checkpoint inhibition. Patients with metastatic PDAC who progressed on chemotherapy were enrolled in one of two treatment arms in a randomized fashion. CRS-207 was given with anti–PD-1 (nivolumab) and anti-CTLA4 (ipilimumab) with (arm A) or without (arm B) GVAX. The primary endpoint was the objective response rate (ORR), and the secondary endpoint was safety. Fifty-seven patients received at least one dose of treatment, with two partial responses (4% ORR), in both arm B. The response rates were not significantly different between the two arms. Related grade ≥3 adverse events were seen in 39 (68%) patients, including 33 events attributed to CRS-207. Mass cytometry analysis of serially obtained biospecimens demonstrated treatment-induced promotion of T-cell memory and infiltration into the tumor microenvironment (TME). Peptide-specific T-cell expansions in vitro, followed by T-cell receptor sequencing, revealed clones specific to MSLN and mutant KRAS within the tumor. Accompanying these antitumor T-cell responses was significant enrichment of myeloid cells. High myeloid and regulatory T-cell signatures correlated with poor responses. We conclude that GVAX/CRS-207 plus nivolumab and ipilimumab successfully generates and expands T-cell clones specific to MSLN and mutant KRAS within the PDAC TME, but immunotherapy-induced myeloid cell enrichment remains a barrier to greater efficacy.See related article by Sidiropoulos et al., p. 399
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Randomized Phase II Study: CRS207/GVAX plus Anti–PD‐1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells into PDAC
Pancreatic ductal adenocarcinoma (PDAC) remains highly lethal and has poor immunogenicity, warranting the use of vaccines to guide and recruit the immune response. Building on prior efforts to achieve clinical immunotherapeutic responses against PDAC, we conducted a phase II study (NCT03190265) that combined attenuated mesothelin (MSLN)-secreting listeria vaccine (CRS-207) and GM-CSF–secreting allogeneic whole-cell vaccine (GVAX) along with checkpoint inhibition. Patients with metastatic PDAC who progressed on chemotherapy were enrolled in one of two treatment arms in a randomized fashion. CRS-207 was given with anti–PD-1 (nivolumab) and anti-CTLA4 (ipilimumab) with (arm A) or without (arm B) GVAX. The primary endpoint was the objective response rate (ORR), and the secondary endpoint was safety. Fifty-seven patients received at least one dose of treatment, with two partial responses (4% ORR), in both arm B. The response rates were not significantly different between the two arms. Related grade ≥3 adverse events were seen in 39 (68%) patients, including 33 events attributed to CRS-207. Mass cytometry analysis of serially obtained biospecimens demonstrated treatment-induced promotion of T-cell memory and infiltration into the tumor microenvironment (TME). Peptide-specific T-cell expansions in vitro, followed by T-cell receptor sequencing, revealed clones specific to MSLN and mutant KRAS within the tumor. Accompanying these antitumor T-cell responses was significant enrichment of myeloid cells. High myeloid and regulatory T-cell signatures correlated with poor responses. We conclude that GVAX/CRS-207 plus nivolumab and ipilimumab successfully generates and expands T-cell clones specific to MSLN and mutant KRAS within the PDAC TME, but immunotherapy-induced myeloid cell enrichment remains a barrier to greater efficacy.See related article by Sidiropoulos et al., p. 399
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses
Supplementary Figure 5. Effects of adding αPD1 to GVAX on myeloid cells.
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses
Supplementary Figure 5. Effects of adding αPD1 to GVAX on myeloid cells.
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses
Supplementary Figure 1. Peripheral blood samples were collected from patients participating in three clinical trials, both before and after two cycles of treatment.
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses
Supplementary Figure 1. Peripheral blood samples were collected from patients participating in three clinical trials, both before and after two cycles of treatment.
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses
Supplementary Figure 2. Directly Analyzable Immune Profile Atlas.
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses
Supplementary Figure 2. Directly Analyzable Immune Profile Atlas.
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses
Supplementary Figure 3. Effects of GVAX on T helper cells and myeloid cells.
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses
Supplementary Figure 3. Effects of GVAX on T helper cells and myeloid cells.
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from A Randomized Phase II Study: CRS207/GVAX plus Anti–PD‐1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells into PDAC
Imaging Mass Cytometry Antibodies
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from A Randomized Phase II Study: CRS207/GVAX plus Anti–PD‐1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells into PDAC
Imaging Mass Cytometry Antibodies